SCHEMBL6260010

SCHEMBL6260010

COc1cc(OC)cc(N2CCN(C(=O)c3cc(NCc4ccccc4)nn3-c3ccccc3)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
DHODH Q02127 2/20 0.47
GFER P55789 2/20 0.46
ENPP2 Q13822 1/20 0.45
ALDH1A1 P00352 3/20 0.44
ACHE P22303 2/20 0.44
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 3/20 0.44
GAA P10253 2/20 0.44
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6261699 0.87 KMT2A (0.50) KMT2ADHODHALDH1A1KDM4EL3MBTL1
SCHEMBL6414102 0.82 KMT2A (0.52) KMT2ADHODHGFERALDH1A1KDM4E
SCHEMBL6265709 0.81 KMT2A (0.59) KMT2AALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6260980 0.81 KMT2A (0.53) KMT2AALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6260121 0.81 KMT2A (0.55) KMT2AALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6263564 0.81 KMT2A (0.55) KMT2AALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6260030 0.80 KMT2A (0.53) KMT2AALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6264113 0.80 ALDH1A1 (0.55) KMT2AALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6263546 0.79 KMT2A (0.56) KMT2AALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6261059 0.79 KMT2A (0.56) KMT2AALDH1A1KDM4EL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590329-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2005-11-02 EP disclosed
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-06-16 US disclosed
WO-2004078732-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AHR, NQO1, ARNT KMT2A 1284/4885DHODH 706/4885GFER 2250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.